3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Exanthema
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Gemcitabine
27
Taxes
9
Capecitabine
8
Albumin-Bound Paclitaxel
6
pembrolizumab
5
Radiosurgery
5
Oxaliplatin
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Specimen Handling
4
Secretin
4
Fluorouracil
4
Drug Therapy
4
Ascorbic Acid
4
durvalumab
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Irinotecan
3
Cyclophosphamide
3
Cisplatin
3
Biopsy
3
palbociclib
2
methylnaltrexone
2
folfirinox
2
fludarabine
2
entinostat
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Pancreatic Neoplasms
×
Doxycycline
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn